STK33

Serine/threonine-protein kinase 33 · Q9BYT3 · STK33 on Sugi Atlas →

2,213 patent compounds predicted against STK33, 1,577 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3847287 SCHEMBL3847287 0.47 11/20
SCHEMBL3903906 SCHEMBL3903906 0.47 10/20
SCHEMBL4826410 SCHEMBL4826410 0.42 10/20
SCHEMBL1903147 SCHEMBL1903147 0.42 10/20
SCHEMBL1905308 SCHEMBL1905308 0.41 10/20
SCHEMBL1307817 SCHEMBL1307817 0.44 9/20
SCHEMBL5507978 SCHEMBL5507978 0.44 8/20
SCHEMBL1903037 SCHEMBL1903037 0.44 8/20
SCHEMBL1904092 SCHEMBL1904092 0.41 8/20
SCHEMBL1903735 SCHEMBL1903735 0.41 8/20
SCHEMBL1898657 SCHEMBL1898657 0.40 8/20
SCHEMBL3844820 SCHEMBL3844820 0.47 7/20
SCHEMBL1901859 SCHEMBL1901859 0.41 7/20
SCHEMBL1509112 SCHEMBL1509112 0.57 6/20
SCHEMBL2135032 SCHEMBL2135032 0.59 5/20
SCHEMBL4313704 SCHEMBL4313704 0.52 5/20
SCHEMBL2740272 SCHEMBL2740272 0.43 5/20
SCHEMBL693527 SCHEMBL693527 0.38 5/20
Pyrimidine Pyrimidine (SCHEMBL3397113) 0.51 4/20
SCHEMBL1898900 SCHEMBL1898900 0.47 4/20

Clinical trials — most relevant to STK33 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions PHASE4UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) PHASE2COMPLETED
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion PHASE2ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma PHASE2ACTIVE_NOT_RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a STK33 binder may also engage these)

ProteinNameSimilarity
Q0VD22 1.000 Q0VD22 →
Q924X7 1.000 Q924X7 →
SNRK SNF-related serine/threonine-protein kinase 0.996 landscape →
Q0DCT8 0.996 Q0DCT8 →
Q66HD5 0.996 Q66HD5 →
Q66I46 0.995 Q66I46 →
A2QHV0 0.995 A2QHV0 →
Q9URY1 0.995 Q9URY1 →
A7A1P0 0.995 A7A1P0 →
A0A1D9QMS2 0.995 A0A1D9QMS2 →
E1B7X9 0.994 E1B7X9 →
Q6NTJ3 0.994 Q6NTJ3 →
F4I4F2 0.994 F4I4F2 →
Q63553 0.994 Q63553 →
Q9C813 0.994 Q9C813 →
Q9TTK0 0.994 Q9TTK0 →
B5VNQ3 0.993 B5VNQ3 →
Q09831 0.993 Q09831 →
Q9NLA1 0.993 Q9NLA1 →
Q39183 0.993 Q39183 →
P22204 0.993 P22204 →
F4JZ68 0.993 F4JZ68 →
Q9TU71 0.993 Q9TU71 →
Q4R7T5 0.993 Q4R7T5 →
A6QQR4 0.993 A6QQR4 →
P22517 0.993 P22517 →
Q7TNL3 0.993 Q7TNL3 →
Q19192 0.993 Q19192 →
Q12152 0.993 Q12152 →
NEK3 Serine/threonine-protein kinase Nek3 0.993 landscape →